Related Experiment Video

Updated: Mar 1, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A

Qiuyue Huang1, Shanshan Qin1, Xiaoning Yuan1

  • 1Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.

Oncology Reports
|June 1, 2017
PubMed

Insights

Arctigenin (Atn), a STAT3 inhibitor, shows promise in treating triple-negative breast cancer (TNBC) by reducing cell growth and inhibiting metastasis. It works by targeting the cancerous inhibitor of protein phosphatase 2A (CIP2A) pathway, reactivating the tumor suppressor PP2A.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) presents a significant therapeutic challenge due to its aggressive nature and limited treatment options.
  • The STAT3 signaling pathway is frequently dysregulated in various cancers, including TNBC, making it a target for novel therapies.
  • Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that inhibits the tumor-suppressive activity of protein phosphatase 2A (PP2A), promoting cancer cell migration and invasion.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying the cytotoxic and anti-metastatic effects of arctigenin (Atn) in TNBC cells.
  • To investigate the role of the CIP2A/PP2A pathway in Atn-mediated inhibition of TNBC metastasis.
  • To evaluate the therapeutic potential of targeting the CIP2A/PP2A axis in TNBC treatment.

Main Methods:

  • In vitro studies using TNBC cell lines treated with arctigenin (Atn).
  • Assessment of cytotoxicity, apoptosis, migration, and invasion.
  • Analysis of key protein expression and phosphorylation levels, including STAT3, CIP2A, PP2A, and Akt.
  • Gene silencing of CIP2A and ectopic expression of CIP2A to modulate pathway activity.
  • Functional assays involving PP2A inhibition.

Main Results:

  • Arctigenin (Atn) demonstrated significant cytotoxicity and inhibited metastasis in TNBC cells.
  • Atn treatment led to the downregulation of CIP2A and reactivation of the tumor suppressor PP2A.
  • Atn-induced anti-metastasis effects were associated with decreased Akt phosphorylation.
  • Silencing CIP2A potentiated Atn's effects on metastasis inhibition and apoptosis.
  • Overexpression of CIP2A or inhibition of PP2A counteracted the therapeutic effects of Atn.

Conclusions:

  • Arctigenin (Atn) exerts its anti-cancer effects in TNBC by inhibiting metastasis through the modulation of the CIP2A/PP2A pathway.
  • The mechanism involves the reactivation of PP2A via CIP2A downregulation, leading to reduced cancer cell migration and invasion.
  • These findings highlight the therapeutic potential of arctigenin and suggest that targeting PP2A reactivation could be a viable anticancer strategy for TNBC.

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

29.9K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K